NVAX (Novavax Inc) Net Profit

Official company branding of Novavax (NVAX)

Novavax, Inc. (NVAX) revenues currently rely on licenses for combination drugs, as demand for COVID-19 vaccines has plummeted. Meanwhile, the company is developing an alternative to mRNA products by utilizing a protein-based method and the Matrix-M adjuvant to enhance immunity. This price action chart confirms that the current figure is -0.24, and the massive operating leverage following R&D expenditures enables the generation of excess profits during mass production.

NVAX (Novavax Pharma) Net Income history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company Novavax (NVAX)

- price and consensus price forecast:
Stock Quotes Novavax Pharma|NVAX - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Novavax Pharma|NVAX - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Novavax|NVAX - Company Net Assets|Market Value to Book Value Ratio novavax.com|NVAX - Company Total Assets
- debt and solvency information:
Total Debt to Capital Coefficient Novavax, Inc.|NVAX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Novavax Inc|NVAX - Company Total Debt|Debts to Book Capitalization Novavax Pharma|NVAX - Company Long-Term Debt|Short-Term Debt Volume Novavax|Immediate Liquidity Ratio novavax.com
- net income and valuation multiples indicators:
NVAX - Company Net Income
Summary company analysis:Novavax, Inc.
Mass-produced product of Novavax Inc

This indicator reflects the actual growth rate of the business's real capital net of all expenses. By analyzing the company's current net result, an investor assesses the business's resilience to bankruptcy and its potential for dividend payments. The metric measures the final financial remainder after covering operating and tax obligations. For Novavax, Inc. (NVAX), this trend confirms the effectiveness of ESG standard integration and bio-waste control. The social mission of equal access to vaccines directly impacts the issuer's long-term profitability.

Main competitors

Net Income Gilead Corp|CDTX (Cidara Therapeutics Inc) - Net Profit|Net Profit curevac.com|Net Income VALN (Valneva)|VIR (Vir Biotechnology Inc) - Final Profit|SIGA Corp - Net Income|Emergent Bio - Company Net Income|Atea Pharmaceuticals - Net Profit|Net Financial Result Invivyd, Inc. IVVD|Enanta Pharmaceuticals, Inc. (ENTA) - Company Net Income|Inovio Pharmaceuticals, Inc. - Final Profit|Net Income HLVX|Net Profit Kalaris Tx|Company Net Income Dyadic International (DYAI)|Net Financial Result nanoviricides.com|Company Net Income Talphera TLPH|COCP: Company Profit|TRAW - Company Net Income|Company Net Income Dogwood Therapeutics, Inc.|QLGN (Qualigen Therapeutics) - Net Income|ALVR (AlloVir) - Company Net Income|VBIV (VBI Vaccines, Inc.) - Net Profit|Net Profit Virios|Net Income VXRT (Vaxart, Inc.)